JNJ-79635322 vs Teclistamab for Multiple Myeloma

(TRIlogy-5 Trial)

This trial aims to compare the effectiveness of a new drug, JNJ-79635322, with an existing treatment, teclistamab, for individuals with multiple myeloma, a type of blood cancer. Participants will receive either JNJ-79635322 or teclistamab as a subcutaneous injection. Suitable candidates for this study include those diagnosed with multiple myeloma, who have undergone 1 to 3 previous treatments, and experience symptoms affecting daily life. The trial seeks to provide improved treatment options for managing multiple myeloma. As a Phase 3 trial, it represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

A previous study found JNJ-79635322 to be generally safe, with most side effects being mild and manageable with proper care. Patients experienced responses similar to those seen with CAR T-cell therapy, suggesting potential effectiveness.

Teclistamab also demonstrated a good safety profile. Research indicated it was well tolerated, with manageable side effects such as cytokine release syndrome (a reaction where the body releases too many proteins too quickly) and some risk of infections. However, no major safety concerns emerged.

Researchers are excited about JNJ-79635322 for multiple myeloma because it represents a novel approach compared to existing treatments like chemotherapy and other monoclonal antibodies. Unlike standard therapies, JNJ-79635322 is a bispecific antibody that targets two different antigens on myeloma cells, potentially leading to more effective tumor cell killing. Additionally, this treatment is administered subcutaneously, which may offer a more convenient and potentially less invasive option compared to traditional intravenous methods. This unique mechanism and delivery method could lead to improved outcomes for patients with multiple myeloma.

This trial will compare JNJ-79635322 and Teclistamab for treating multiple myeloma. Research has shown that JNJ-79635322 is promising, with 86.1% of patients who had already received many treatments responding to it. Most patients experienced a positive effect. Meanwhile, Teclistamab has proven effective, with about 65% of patients seeing at least a partial improvement. Additionally, nearly 70% of patients treated with Teclistamab did not experience disease progression after 18 months. Both treatments, tested in separate arms of this trial, have shown significant potential in managing multiple myeloma.²⁵⁶⁷⁸